Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.54 - $0.92 $216 - $368
-400 Reduced 28.57%
1,000 $0
Q2 2024

Aug 14, 2024

SELL
$1.0 - $1.45 $1,400 - $2,030
-1,400 Reduced 50.0%
1,400 $1,000
Q1 2024

May 15, 2024

SELL
$1.02 - $3.23 $5,508 - $17,442
-5,400 Reduced 65.85%
2,800 $3,000
Q4 2023

Feb 14, 2024

BUY
$1.72 - $3.18 $3,268 - $6,042
1,900 Added 30.16%
8,200 $22,000
Q3 2023

Nov 14, 2023

BUY
$2.13 - $5.55 $13,206 - $34,410
6,200 Added 6200.0%
6,300 $14,000
Q2 2023

Aug 14, 2023

SELL
$3.6 - $5.25 $41,760 - $60,900
-11,600 Reduced 99.15%
100 $0
Q1 2023

May 15, 2023

BUY
$4.3 - $8.27 $47,730 - $91,797
11,100 Added 1850.0%
11,700 $52,000
Q4 2022

Feb 14, 2023

SELL
$5.66 - $8.42 $90,560 - $134,720
-16,000 Reduced 96.39%
600 $5,000
Q3 2022

Nov 14, 2022

SELL
$3.02 - $6.12 $17,818 - $36,108
-5,900 Reduced 26.22%
16,600 $102,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $108M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.